Table 6 |
|||||||
|
Novel agents in clinical trials |
|||||||
|
Study Agents |
Other agents |
Disease |
Dosage |
Clinical trails |
No Pts |
Response |
Reference |
|
|
|||||||
|
CPX-351 (liposomal cytarabine: daunorubicin at 5:1) |
Elderly untreated AML |
100 u/m2 D1,3,5 |
Phase IIb |
45 |
acceptable toxicity and comparable to standard regimen |
[9] |
|
|
Voreloxin (anticancer quinolone derivative) |
Elderly untreated AML |
72 mg/m2 qw × 3 |
Phase II |
105 |
CR/CRp: 47% |
[45] |
|
|
Amonafide (AS1413) |
Cytarabine |
Secondary AML |
600 mg/m2/d IV d1-5 |
Phase II |
88 |
CR/CRi: 42% |
[46] |
|
behenoylara-C |
Idarubicin Etoposide |
untreated AML |
300-350 mg/m2 × 10d |
Phase II |
165 |
CR: 87% |
[47] |
|
Lenalidomide |
Cytarabine, Daunorubicin |
5q-AML/MDS |
10 mg/d po d1-21 |
Phase I/II |
18 |
CR/CRi: 47% |
[50] |
|
Ribavirin |
Cytarabine |
AML |
13 |
CR:7% |
[51] |
||
|
ARRY-520 |
idarubicin |
refractory AML |
0.8-5.6 mg/m2 IV |
Phase I |
33 |
MTD: 4.5 mg/m2 |
[52] |
|
AZD1152 |
relapsed AML |
50 mg-1600 mg |
Phase I/II |
64 |
MTD: 1200 mg |
[53] |
|
|
AZD6244 |
AML |
100 mg po bid |
Phase II |
47 |
Feasible treatment |
[56] |
|
|
Terameprocol |
relapsed and refractory AML |
1000-2200 mg iv, 3/w, ×2-3w |
Phase I/II |
16 |
MTD: 1500 mg |
[57] |
|
|
|
|||||||
|
Abbreviations: CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose; |
|||||||
|
Zhu et al. Journal of Hematology & Oncology 2010 3:17 doi:10.1186/1756-8722-3-17 |
|||||||
